Design and Synthesis of N-Substituted Indazole-3-Carboxamides as Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors†
作者:Maulik R. Patel、Kashyap G. Pandya、Cesar A. Lau-Cam、Satyakam Singh、Maria A. Pino、Blase Billack、Kurt Degenhardt、Tanaji T. Talele
DOI:10.1111/j.1747-0285.2011.01302.x
日期:2012.4
A group of novel N‐1‐substituted indazole‐3‐carboxamide derivatives were synthesized and evaluated as inhibitors of poly(ADP‐ribose)polymerase‐1 (PARP‐1). A structure‐based design strategy was applied to a weakly active unsubstituted 1H‐indazole‐3‐carboxamide 2, by introducing a three carbon linker between 1H‐indazole‐3‐carboxamide and different heterocycles, and led to compounds 4 [1‐(3‐(piperidin
合成了一组新颖的N -1取代的吲唑-3-羧酰胺衍生物,并将其评估为聚(ADP-核糖)聚合酶-1(PARP-1)的抑制剂。通过在1 H-吲唑-3-羧酰胺和不同的杂环之间引入三个碳连接基,将基于结构的设计策略应用于弱活性的未取代1 H-吲唑-3-羧酰胺2,并导致化合物4 [1– (3-(哌啶-1-基)丙基)-1 ħ -吲唑-3-甲酰胺,IC 50 = 36μ米]和5 [1-(3-(2,3- dioxoindolin -1-基)丙基) -1 ħ -吲唑-3-甲酰胺,IC 50 = 6.8μ米]。在大鼠中评估了化合物5对已知的致糖尿病药物链脲佐菌素的治疗所诱导的对糖尿病的保护作用。除了保持胰腺分泌胰岛素的能力外,化合物5还能够在很大程度上减轻随后的高血糖反应。